drugset / Trial / NCT05886998

Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury

NCT05886998

Phase 3 Completed 88 enrolled Ain Shams University
RandomizedParallel-groupTriple-blindPrevention

Summary

This study aims to examine the effects of nebulized heparin on the clinical outcomes in adult patients suffering smoke inhalation injury. Patients will be randomized to receive nebulized heparin or an equal volume of normal saline for 14 days and the incidence of acute lung injury will be compared in either group.

Timeline

Start
2023-06-01
Primary completion
2024-06-03
Completion
2024-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified 5000 iu Other

Indications